336 related articles for article (PubMed ID: 31385933)
21. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
22. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
23. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
[TBL] [Abstract][Full Text] [Related]
24. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
25. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
26. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.
Choi AY; Manook M; Olaso D; Ezekian B; Park J; Freischlag K; Jackson A; Knechtle S; Kwun J
Front Immunol; 2021; 12():694763. PubMed ID: 34177960
[TBL] [Abstract][Full Text] [Related]
27. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
28. Subclinical antibody-mediated rejection due to anti-human-leukocyte-antigen-DR53 antibody accompanied by plasma cell-rich acute rejection in a patient with cadaveric kidney transplantation.
Katsuma A; Yamamoto I; Komatsuzaki Y; Niikura T; Kawabe M; Okabayashi Y; Yamakawa T; Katsumata H; Nakada Y; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():31-4. PubMed ID: 26971538
[TBL] [Abstract][Full Text] [Related]
29. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
30. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
31. Frequency of Human Leukocyte Antigens and Donor Specific Antibodies in Long-Term Living Donor Kidney Transplantation.
Alagoz S; Seyahi N
Transplant Proc; 2019 Sep; 51(7):2302-2307. PubMed ID: 31358448
[TBL] [Abstract][Full Text] [Related]
32. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
Arnold ML; Ntokou IS; Doxiadis II; Spriewald BM; Boletis JN; Iniotaki AG
Transpl Int; 2014 Mar; 27(3):253-61. PubMed ID: 24118579
[TBL] [Abstract][Full Text] [Related]
33. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
34. Donor-specific anti-HLA antibodies in pediatric renal transplant recipients with creeping creatinine: Prevalence, histological correlations, and impact on patient and graft survival.
Monteverde ML; Chaparro A; Goldberg J; Marcos CY; Padros K; Balbarrey Z; Briones L; Rush D
Pediatr Transplant; 2015 Nov; 19(7):684-90. PubMed ID: 26212912
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.
Crespo M; Zárraga S; Alonso Á; Beneyto I; Díaz Corte C; Fernandez Rodriguez AM; Franco A; Hernández D; González-Roncero FM; Jiménez Martín C; Jimeno L; Lauzurica Valdemoros LR; Llorente S; Mazuecos A; Osuna A; Ramos JP; Rodríguez Benot A; Ruiz San Millán JC; Sánchez Fructuoso A; Torregrosa JV; Guirado L;
Transplantation; 2020 Aug; 104(8 Suppl 2):S1-S12. PubMed ID: 32658025
[No Abstract] [Full Text] [Related]
36. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
38. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
39. [Role of antibodies in kidney transplant].
Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
[TBL] [Abstract][Full Text] [Related]
40. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]